JP2008526189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526189A5 JP2008526189A5 JP2007548838A JP2007548838A JP2008526189A5 JP 2008526189 A5 JP2008526189 A5 JP 2008526189A5 JP 2007548838 A JP2007548838 A JP 2007548838A JP 2007548838 A JP2007548838 A JP 2007548838A JP 2008526189 A5 JP2008526189 A5 JP 2008526189A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- nucleic acid
- promoter
- cell
- acid encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims 79
- 150000007523 nucleic acids Chemical class 0.000 claims 54
- 108020004707 nucleic acids Proteins 0.000 claims 53
- 102000039446 nucleic acids Human genes 0.000 claims 53
- 210000004027 cell Anatomy 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 17
- 108010078791 Carrier Proteins Proteins 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 230000032823 cell division Effects 0.000 claims 13
- 230000002950 deficient Effects 0.000 claims 11
- 230000005855 radiation Effects 0.000 claims 11
- 101710155188 Hexon-interlacing protein Proteins 0.000 claims 10
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 230000010076 replication Effects 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 230000002074 deregulated effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims 3
- 102000004594 DNA Polymerase I Human genes 0.000 claims 3
- 108010017826 DNA Polymerase I Proteins 0.000 claims 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 3
- 230000022131 cell cycle Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 3
- 230000029812 viral genome replication Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 206010020843 Hyperthermia Diseases 0.000 claims 2
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 108010082820 apicidin Proteins 0.000 claims 2
- 229930186608 apicidin Natural products 0.000 claims 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 2
- 229960003094 belinostat Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 230000036031 hyperthermia Effects 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims 1
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 claims 1
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 101150066038 E4 gene Proteins 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 claims 1
- 229940121849 Mitotic inhibitor Drugs 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- -1 anticalins Proteins 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 238000012512 characterization method Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims 1
- 229950009213 rubitecan Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004063662 | 2004-12-31 | ||
| DE102004063662.1 | 2004-12-31 | ||
| PCT/EP2006/000010 WO2006070024A2 (de) | 2004-12-31 | 2006-01-02 | E1 -minus adenoviren und deren verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526189A JP2008526189A (ja) | 2008-07-24 |
| JP2008526189A5 true JP2008526189A5 (enExample) | 2009-02-19 |
| JP5435871B2 JP5435871B2 (ja) | 2014-03-05 |
Family
ID=36615284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548838A Expired - Lifetime JP5435871B2 (ja) | 2004-12-31 | 2006-01-02 | Ｅ１−マイナスアデノウイルス及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20090232800A1 (enExample) |
| EP (1) | EP1830864A2 (enExample) |
| JP (1) | JP5435871B2 (enExample) |
| CA (1) | CA2610360A1 (enExample) |
| WO (1) | WO2006070024A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| EP1689445B1 (de) | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| EP1831382B1 (en) | 2004-12-31 | 2023-01-18 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| SI1901729T1 (sl) * | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| CN101868446A (zh) * | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| SI2262493T1 (sl) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| DK2403951T3 (en) * | 2009-03-02 | 2016-01-11 | Univ California | Tumor-selective E1a and E1b adenoviral mutants |
| JP2011111435A (ja) * | 2009-11-30 | 2011-06-09 | Joy Up:Kk | 神経芽腫又は膠芽腫の治療薬 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| US10906957B2 (en) * | 2016-09-27 | 2021-02-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE386130T1 (de) * | 1995-03-24 | 2008-03-15 | Genzyme Corp | Adenovirale vektoren für die gentherapie |
| US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US6955808B2 (en) * | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
| CA2478508C (en) * | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| AU2003242585A1 (en) * | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| PL219321B1 (pl) * | 2002-10-15 | 2015-04-30 | Per Sonne Holm | Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny |
| EP1616016B1 (en) * | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| EP1689445B1 (de) * | 2003-11-14 | 2015-02-25 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierende nukleinsäuren |
| WO2005052143A2 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| WO2006065827A2 (en) * | 2004-12-13 | 2006-06-22 | Canji, Inc. | Cell lines for production of replication-defective adenovirus |
| EP1831382B1 (en) * | 2004-12-31 | 2023-01-18 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| WO2007103825A2 (en) * | 2006-03-02 | 2007-09-13 | The Board Of Regents Of The University Of Texas System | Combination therapy with oncolytic adenovirus |
-
2006
- 2006-01-02 US US11/813,089 patent/US20090232800A1/en not_active Abandoned
- 2006-01-02 WO PCT/EP2006/000010 patent/WO2006070024A2/de not_active Ceased
- 2006-01-02 EP EP06700409A patent/EP1830864A2/de not_active Ceased
- 2006-01-02 JP JP2007548838A patent/JP5435871B2/ja not_active Expired - Lifetime
- 2006-01-02 CA CA002610360A patent/CA2610360A1/en not_active Abandoned
-
2011
- 2011-07-19 US US13/186,290 patent/US20120039877A1/en not_active Abandoned
-
2017
- 2017-03-17 US US15/462,133 patent/US20170190752A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11268073B2 (en) | Use of adenovirus and nucleic acids coding therefor | |
| JP5873893B2 (ja) | アデノウイルスおよびそれをコードしている核酸の新たな使用 | |
| JP2011200234A (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| AU2010257327C1 (en) | Adenovirus expressing genes in reverse order and use thereof | |
| JP2008526188A5 (enExample) | ||
| JP5435871B2 (ja) | Ｅ１−マイナスアデノウイルス及びその使用 | |
| JP2007511212A5 (enExample) | ||
| JP2006512284A5 (enExample) | ||
| EP1831382A2 (en) | Method for reversing multiple resistance in animal cells | |
| WO2012022496A2 (en) | Method for killing tumor stem cells | |
| AU2015201828B2 (en) | Novel use of adenoviruses and nucleic acids coding therefor |